What are the detailed pharmacokinetic properties of amisulpride, including absorption, bioavailability, distribution, metabolism, elimination, half-life, and dosing considerations in renal impairment?

Pharmacokinetics of Amisulpride

Amisulpride exhibits linear pharmacokinetics with minimal metabolism, predominantly undergoing renal elimination as unchanged drug, with a bioavailability of 48%, low protein binding of 17-30%, and an elimination half-life of approximately 4-5 hours for intravenous formulations and 12 hours for oral formulations. 1, 2

Absorption

• Bioavailability: Oral amisulpride demonstrates 48% bioavailability 2
• Peak concentrations: Following intravenous infusion, peak plasma concentration is achieved at the end of infusion, then decreases to approximately 50% within 15 minutes 1
• Dose proportionality: AUC increases dose-proportionally in the range of 5-40 mg IV 1

Distribution

• Volume of distribution:
  • 127-144 L in surgical patients
  • 171 L in healthy subjects 1
• Protein binding: 17% (oral studies) 2 to 25-30% (IV studies) in the concentration range of 37-1850 ng/mL 1
• Tissue distribution: Amisulpride distributes into erythrocytes 1

Metabolism

Amisulpride undergoes minimal metabolism—this is a critical pharmacokinetic feature. 1, 3

• No metabolites are detectable in plasma 1, 3
• Four minor metabolites identified in urine and feces, each accounting for <7% of the dose 1
• Not metabolized by major cytochrome P450 enzymes (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4) 1
• Approximately 75% metabolized by the liver in oral formulations 2

Elimination

Renal excretion is the primary elimination pathway:

• 74% recovered in urine (58% as unchanged drug) 1, 3
• 23% recovered in feces (20% as unchanged drug) 1, 3
• Total recovery: 96.4% (range 92.0-98.5%) 3
• Renal clearance: 20.5 L/hr (342 mL/min), indicating active renal secretion 1
• Plasma clearance: 20.6 L/h in surgical patients, 24.1 L/h in healthy subjects 1

Elimination Pattern

• Biphasic excretion:
  • Initial rapid phase: approximately two-thirds eliminated within 12 hours, primarily urinary 3
  • Second slower phase: predominantly fecal, essentially complete by 96 hours 3

Half-Life

• Intravenous formulation: 4-5 hours 1, 3
• Oral formulation: Approximately 12 hours 2
• Terminal elimination half-life of total 14C-labeled drug material: 4.2 hours 3

Special Populations

Renal Impairment

Dose adjustment is NOT required for mild to moderate renal impairment, but exposure increases with severity: 1

• Severe renal impairment (eGFR <30 mL/min/1.73 m²):

  • Cmax: Not significantly increased compared to normal renal function
  • AUC: Approximately 2-fold increase
  • Changes not considered clinically meaningful for single doses 1

• Mild to moderate renal impairment (eGFR 30-89 mL/min/1.73 m²):

  • Cmax: No significant difference
  • AUC: Approximately 1.3-fold increase
  • Not clinically meaningful 1

Age Effects

Age significantly affects amisulpride clearance—this is clinically important for dosing: 4, 5

• Clearance decreases with increasing age 4, 5
• Population pharmacokinetic model: CL/F = 1.04 × (AGE/32)^-0.624 (L/h) 5
• Recommended maximum doses to avoid exceeding laboratory alert level (640 ng/mL):
  • Age ≥60 years: ≤600 mg/day
  • Age 40 years: ≤800 mg/day
  • Age 20 years: ≤1200 mg/day 5
• No clinically significant effect on IV pharmacokinetics based on age 18-90 years in FDA studies 1

Body Weight

• Lean body weight (LBW) significantly increases clearance 4
• Patients aged >75 years with LBW of 30 kg receiving 200 mg twice daily had trough concentrations above reference range in 82% of cases 4

Sex and Race

• No clinically significant effect on pharmacokinetics 1

Hepatic Impairment

• Not studied in persons with hepatic dysfunction for IV formulations 1

Drug Interactions

Amisulpride has minimal drug interaction potential via cytochrome P450 pathways: 1

As Perpetrator:

• Does not inhibit: CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4
• Does not induce: CYP1A2, CYP2C9, CYP2C19, CYP3A4
• Inhibits MATE1 and MATE2-K transporters (potential interaction with metformin, other MATE substrates)
• Does not inhibit: P-gp, BCRP, OCT1, OCT2, OAT1, OAT3, OATP1B1, OATP1B3

As Victim:

• Substrate for: P-gp, BCRP, OCT1, MATE1, MATE2-K
• Not a substrate for: OATP1B1, OATP1B3, OAT1, OAT3, OCT2, major CYP450 enzymes

Clinical Pharmacokinetic Parameters

Following single IV doses in patients and healthy subjects 1:

Dose	Infusion Duration	Cmax (ng/mL)	AUC (ng·h/mL)
5 mg	1-2 min	161 (patients)	260 (patients)
5 mg	2 min	200 (healthy)	154 (healthy)
10 mg	1-2 min	285 (patients)	401 (patients)
10 mg	1 min	451 (healthy)	136 (healthy)

Key Clinical Implications

1. Renal function monitoring is essential given predominant renal elimination and active secretion
2. Age-based dose adjustment should be considered to avoid supratherapeutic concentrations
3. Low drug interaction potential via CYP450 enzymes, but monitor MATE1/MATE2-K substrate drugs
4. Linear pharmacokinetics allow predictable dose adjustments
5. Minimal metabolism reduces variability from genetic polymorphisms in metabolizing enzymes